This report describes a usually mild syndrome, dubbed LICATS, affecting about three-quarters of CAR T-cell recipients.

Long-term data gathered from the TRANSCEND NHL trial have shown that this treatment approach can significantly improve ...

T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety ...

A novel off-the-shelf CAR NK therapy using logic gates has shown complete remissions in relapsed AML patients, according to ...

Researchers from the Keck School of Medicine of USC have developed an advanced analytical tool using spectral flow cytometry to analyze CAR T cells, revealing that a five-day expansion process ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing their ability to infiltrate solid tumours.

Scientists from the Keck School of Medicine at University of Southern California have developed a spectral flow ...

Researchers sought to assess the access to CAR-T therapy for patients within community-based and transplant cell therapy networks.

bound to Cas9-RNP, is then delivered to cells to promote precise knock-in via homology-directed repair. This method significantly enhances the precision and efficiency of CAR T cell production.

Chimeric antigen receptor (CAR) T cell therapies have made remarkable strides in treating high-risk B-cell malignancies since the first CAR-T, Novartis’ Kymriah (tisagenlecleucel), was approved ...